Anlon Healthcare (NSE:AHCL) Other Long Term Assets: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AHCL Anlon Healthcare Ltd NSE:AHCL
21 GF Score
Price ₹15.61
! 5 Warning Signs
View Full Analysis

What is Anlon Healthcare Other Long Term Assets?

Anlon Healthcare NSE:AHCL +0.84% 21 Other Long Term Assets is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:AHCL with a GF Score™ of 21/100. The stock has 5 warning signs investors should review.

Anlon Healthcare's other long-term assets for the quarter that ended in Jun. 2026 was ₹0 Mil.

Anlon Healthcare's quarterly other long-term assets increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹188 Mil) but then stayed the same from Mar. 2026 (₹188 Mil) to Jun. 2026 (₹0 Mil).

Anlon Healthcare's annual other long-term assets increased from Mar. 2024 (₹-0 Mil) to Mar. 2025 (₹0 Mil) and increased from Mar. 2025 (₹0 Mil) to Mar. 2026 (₹188 Mil).

Anlon Healthcare Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Anlon Healthcare's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anlon Healthcare Other Long Term Assets Chart

Anlon Healthcare Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Other Long Term Assets
-0.00 -0.00 -0.00 0.00 188.37

Anlon Healthcare Quarterly Data
Mar22 Mar23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 188.37 0.00
NSE:AHCL
21GF Score
Anlon Healthcare Ltd NSE:AHCL
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anlon Healthcare Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of ₹0 Mil mean?
Anlon Healthcare (NSE:AHCL) has a Other Long Term Assets of ₹0 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Anlon Healthcare and its competitors.
Is Anlon Healthcare's Other Long Term Assets too high?
Anlon Healthcare's current Other Long Term Assets is ₹0 Mil. Overall, Anlon Healthcare has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's Other Long Term Assets compare to ZTS?
Anlon Healthcare's Other Long Term Assets of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Drug Manufacturers company?
A good Other Long Term Assets depends on the Drug Manufacturers industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Anlon Healthcare and its competitors. Anlon Healthcare's current Other Long Term Assets is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current Other Long Term Assets of ₹0 Mil. The current Other Long Term Assets is ₹0 Mil. Anlon Healthcare's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current Other Long Term Assets is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anlon Healthcare Business Description

Other Exchanges 544497:India
Address Kalawad Road, 101/102, Silvercoin Complex, Opposite Crystal Mall, Rajkot, GJ, IND, 360 005
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
21GF Score

Get the complete analysis for NSE:AHCL

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹15.61
Price